Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

CLÉ DE PEAU BEAUTÉ RADIANT CREAM FOUNDATION - Health Canada Drug Approval Details

Approvals/Health Canada/CLÉ DE PEAU BEAUTÉ RADIANT CREAM FOUNDATION

Authorized

STANDARD

CLÉ DE PEAU BEAUTÉ RADIANT CREAM FOUNDATION

shiseido americas corporation dist🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: d09e18ebe674994e
Company: shiseido americas corporation dist
Type: Standard

Approval Details

Approval Id: d09e18ebe674994e
Drug Approval Canada Name: CLÉ DE PEAU BEAUTÉ RADIANT CREAM FOUNDATION
Product Name: CLÉ DE PEAU BEAUTÉ RADIANT CREAM FOUNDATION
Status: Cancelled Post Market
Status Date: 2022-08-05
Original Market Date: 2016-07-25
Din: 02446952
Drug Class: Human
Dosage Form: Cream
Route Of Administration: Topical
Schedule: OTC
Ahfs: 84:80.00
Atc Original: D02BA30 COMBINATIONS OF PROTECTIVES AGAINST UV-RADIATION
Atc Name: d 02 ba 30
Aig Number: 0216790145
Company Name: shiseido americas corporation dist
Company Address: 900 Third Avenue, New York, New York, United States, 10017

Active Ingredients

OCTINOXATE

4.4 % / W/W

TITANIUM DIOXIDE

1.2 % / W/W

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

d09e18ebe674994e

Type

Standard

Back to Health Canada Approvals